I-MAB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.5 USD | -5.06% |
|
-12.02% | -21.05% |
| Jun. 06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
| Jun. 05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Neutral |
| Resistance | 1.680 | 1.900 | 2.130 |
| Spread/Res. | -10.71% | -21.05% | -29.58% |
| Spread/Supp. | +2.04% | +15.38% | +25.00% |
| Support | 1.470 | 1.300 | 1.200 |
Technical Rankings Surperformance
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- IMAB Stock
- Charts I-Mab
